Ligand induced upregulation of the type II transforming growth factor (TGF-β) receptor enhances TGF-β responsiveness in COLO-357 cells

Pancreas

Volumn 18, Issue 4, 1999, Pages 364-370

  Kleeff, Jörg ^a   Wildi, Stefan ^a   Friess, Helmut ^b   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Pancreatic cancer; Smad4; TGF ; TGF receptor regulation

Indexed keywords

RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 0032939213     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199905000-00006     Document Type: Article

References (40)

1. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
2. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990;6:597-641.
3. Derynck R. TGF-β-receptor-mediated signaling. Trends Biochem Sci 1994;19:548-53.
4. Wrana JL, Attisano L, Wiser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-7.
5. Heldin C-H, Miyazono K, tenDijke K. TGF-β signalling from cell membrane to nucleus trough SMAD proteins. Nature 1997;390: 465-71.
6. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGF-β-inducible transcriptional complexes. Genes Dev 1997;11:3157-67.
7. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-3.
8. Grau AM, Zhang L, Wang W, et al. Induction of p21waf1 expression and growth inhibition by transforming factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-34.
9. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993;8:23-34.
10. Wagner M, Kleeff J, Lopez ME, Bockman I, Massague J, Korc M. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 1998;78:255-60.
11. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8.
12. Kleeff J, Korc M. Up-regulation of transforming growth factor-β receptors by TGF-β1 in COLO-357 cells. J Biol Chem 1998;273: 7495-500.
13. Raitano AB, Korc M. Tumor necrosis factor up-regulates gamma-interferon binding in a human carcinoma cell line. J Biol Chem 1990;265:10466-72.
14. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler MW, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
15. Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of the DPC4 gene in human colorectal cancer in vivo. Gastroenterology 1996;111:1369-72.
16. Wrana JL, Attisano L, Carcamo J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71: 1003-14.
17. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
18. Kleeff J, Ishiwata T, Friess H, Büchler MW, Korc M. Concomitant overexpression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860-8.
19. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-52.
20. Steiner MS, Barrack ER. Transforming growth factor-β overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
21. Friess H, Yamanaka Y, Buchler M. et al. Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
22. Arteaga CJ, Carty-Dugger T, Moses HL, Herd SD, Pietenpol JL. Transforming growth factor-β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993;4:193-201.
23. Takanami I, Tanaka F, Hashizume T, et al. Transforming growth factor-beta isoforms expression in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology 1997;54:122-8.
24. Moretti S, Pinzi C, Berti E, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997;7:313-21.
25. Kloen P, Gebhardt MC, Perez-Atayde A, et al. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. Cancer 1997;80: 2230-9.
26. Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 1996;56:44-8.
27. Wang J, Han W, Zborowska E, et al. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells, J Biol Chem 1996;271: 17366-71.
28. Markowitz S, Wang J, Meyerhoff L, et al. Inactivation of the TGF-β type II receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
29. Meyerhoff LL, Parsons R, Kim A-J, et al. A transforming growth factor-β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-7.
30. Boyer JC, Umar A, Risinger JI, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 1995;55:6063-70.
31. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-4.
32. Maesawa C, Tamura G, Nishizuka S, et al. MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res 1997;88:340-3.
33. Powell SM, Harper JC, Hamilton SR, Robinson CR, Cummings OW. Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997;57:4221-4.
34. Wisotzkey RG, Mehra A, Sutherland DJ, et al. Medea is a Drosophila Smad4 homolog that is differentially required to potentiate DPP responses. Development 1998;125:1433-45.
35. Hudson JB, Podos SD, Keith K, Simpson SL, Ferguson EL. The Drosophila Medea gene is required downstream of dpp and encodes a functional homolog of human Smad4. Development 1998; 125:1407-20.
36. Das P, Maduzia LL, Wang H, et al. The Drosophila gene Medea demonstrates the requirement for different classes of Smads in dpp signaling. Development 1998;125:1519-28.
37. Saitoh M, Nishitoh H, Amagasa T, Miyazono K, Takagi M, Ichijo H. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling path-ways of transforming growth factor-beta. J Biol Chem 1996;271: 2769-75.
38. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor beta-induced phosphorylation of Smac3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 1997;94:10669-74.
39. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
40. Lu Z, Friess H, Graber HU, Guo X, et al. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.